Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Revision Trapeziometacarpal Arthroplasty With Acellular Dermal Xenograft.

Created on 07 Aug 2026

Authors

Michael C Doarn, Mariel McLaughlin McArthur, John J Fernandez

Published in

Eplasty. Volume 26. Pages e2. Epub Feb 04, 2026.

Abstract

Osteoarthritis of the trapeziometacarpal joint is common. There are limited surgical options for patients who have undergone a failed primary trapeziometacarpal arthroplasty.
The authors conducted a retrospective review of patients who received a porcine dermal graft for failed trapeziometacarpal arthroplasty. Three hundred fifty-five trapeziometacarpal procedures were performed from 2005 to 2015; 9 were revisions. Seven were performed with xenograft interposition. Data included primary procedure, grip and key pinch strength, Visual Analog Score (VAS), motion, time to return to work, Kapandji Score, and radiographs.
The mean follow-up was 84 weeks. The mean VAS score was 2.3, and all patients reported notable improvement. The mean Kapandji Score was 8. The mean grip was 20 kg, and the mean key pinch was 5 kg in the operated hand. The mean time to return to work was 12 weeks. The final radiographs showed improvement in spaces. No complications or immunological reactions were encountered.
The authors describe a technique for revision trapeziometacarpal arthroplasty with a porcine xenograft acellular dermal matrix. This technique shows a safe and valid treatment option with acceptable clinical outcomes.

PMID:
42564597
Bibliographic data and abstract were imported from PubMed on 07 Aug 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement